The earnings call reflects a positive outlook with significant progress in the clinical development of fadra and a strong financial position, despite some challenges in R&D tax credits and increased expenses for topogezotitib.

Company Guidance -

Q2 2025

During the Cyclacel Q2 2024 earnings call, the company provided key updates on their precision medicine strategy, particularly focusing on fadra, an oral CDK2/9 inhibitor. Recruitment is progressing well in the 065-101 Phase II proof-of-concept study, with an enriched cohort targeting patients with CDKN2A and CDK NIB chromosomal abnormalities. Initial clinical activity results are expected in Q4 2024. Financially, Cyclacel reported cash equivalents of $6 million as of June 2024, with net cash used in operating activities amounting to $3.6 million for the first half of the year, indicating a decrease from $8.2 million in the same period of 2023. Research and development expenses for the quarter were $2 million, a reduction from $4.7 million in Q2 2023, with specific R&D expenses for fadra at $1.5 million, down from $3 million the previous year. The company anticipates that current cash resources will cover planned programs into the fourth quarter of 2024.

Progress in Fadra Phase II Study

Cyclacel reported successful recruitment in the enriched cohort of their Phase II proof-of-concept study for fadra, with positive preliminary signals in heavily pretreated patients across various cancer types. Initial clinical activity is expected to be reported in Q4 2024.

Strong Financial Position

Cyclacel's cash equivalents increased to $6 million as of June 2024, compared to $3.4 million at the end of 2023. The company raised $6.3 million through financing activities.

Reduced Net Loss

Net loss for the quarter was reduced to $3.3 million compared to $5.5 million in the same period of 2023.

Cyclacel Pharmaceuticals (CYCC) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

CYCC Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Aug 06, 2025	2025 (Q2)	- / -	-0.72	―	―	―
May 07, 2025	2025 (Q1)	- / -	-2.27	―	―	―
Apr 02, 2025	2024 (Q4)	-69.60 / 0.00	-544.8	―	―	―
Nov 12, 2024	2024 (Q3)	-129.60 / -43.20	-1764	97.55% (+1720.80)	―	―
Aug 14, 2024	2024 (Q2)	-344.40 / -172.80	-1584	89.09% (+1411.20)	―
May 14, 2024	2024 (Q1)	-1138.80 / -544.80	-1692	67.80% (+1147.20)	―
Mar 19, 2024	2023 (Q4)	-1414.40 / -1495.20	-2160	30.78% (+664.80)	―
Nov 13, 2023	2023 (Q3)	-1308.00 / -1764.00	-1512	-16.67% (-252.00)	―
Aug 09, 2023	2023 (Q2)	-1812.00 / -1584.00	-1656	4.35% (+72.00)	―
May 11, 2023	2023 (Q1)	-2388.00 / -1692.00	-1512	-11.90% (-180.00)	―

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

CYCC Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
May 07, 2025	$84.96	$76.34	-10.15%
Apr 02, 2025	$58.85	$55.20	-6.20%
Nov 12, 2024	$98.40	$108.00	+9.76%
Aug 14, 2024	$348.00	$316.80	-8.97%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Cyclacel Pharmaceuticals (CYCC) report earnings?

Cyclacel Pharmaceuticals (CYCC) is schdueled to report earning on Aug 06, 2025, TBA (Confirmed).

What is Cyclacel Pharmaceuticals (CYCC) earnings time?

Cyclacel Pharmaceuticals (CYCC) earnings time is at Aug 06, 2025, TBA (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is CYCC EPS forecast?

Currently, no data Available

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing